Month: September 2026

OLD GREENWICH, Conn., Sept. 17, 2026 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) (“Star” or the “Company”), a diversified holding company, announced today that its management team will present and host one-on-one meetings with investors at two upcoming conferences.

• Virtual Sidoti Small Cap Conference: September 23 – 24, 2026.
  Star’s main presentation is scheduled for Thursday, September 24 at 9:15am ET. Investors can access the live presentation by clicking here.

• Noble Capital Markets’ Emerging Growth Virtual Equity Conference: October 1-2, 2026.
  Star’s main presentation is scheduled for Thursday, October 1 at 11:00am ET. Attendees interested in viewing the live presentation can join directly by clicking here.

Management will also host virtual one-on-one meetings with investors during both conferences.

Investors can download a PDF copy of the presentation by visiting Star’s Investor Relations section of the website www.starequity.com.

About Star Equity Holdings, Inc.

Star Equity Holdings, Inc. is a diversified holding company that seeks to build long-term shareholder value by acquiring, managing, and growing businesses with strong fundamentals and market opportunities. Its current structure comprises four segments: Building Solutions, Business Services, Energy Services, and Investments. For more information visit www.starequity.com.

Building Solutions

The Building Solutions division operates in three specialties: (i) modular building manufacturing; (ii) structural wall panel and wood foundation manufacturing, including building supply distribution operations; and (iii) glue-laminated timber (glulam) column, beam, and truss manufacturing.

Business Services

The Business Services division provides flexible and scalable recruitment solutions to a global clientele, servicing organizations at all levels, from entry-level positions to the C-suite. The division focuses on mid-market and enterprise organizations worldwide, partnering consultatively with talent acquisition, HR, and procurement leaders to build diverse, high-impact teams and drive business success.

Energy Services

The Energy Services division engages in the rental, sale, and repair of downhole tools used in the oil and gas, geothermal, mining, and water-well industries.

Investments
The Investments division manages and finances the Company’s real estate assets as well as its investment positions in private and public companies.

For more information contact:

The Equity Group

Lena Cati

Senior Vice President

212-836-9611

lena.cati@theequitygroup.com

ARCO, Italy, Sept. 17, 2026 (GLOBE NEWSWIRE) — Aquafil S.p.A. (MI: ECNL) (OTCQX: ECNLF), a pioneer in the circular economy also thanks to the ECONYL^® regeneration system, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Company Webcast

The webcast presentation will take place at 12:30 p.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/O75XQy8kpVM. The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings on September 29, 2026. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/fall2026invreg/.

About Aquafil S.p.A.

Aquafil is a pioneer in the circular economy also thanks to the ECONYL^® regeneration system, an innovative and sustainable process able to create new products from waste and give life to an endless cycle. The nylon waste is collected in locations all over the world and includes industrial waste but also products – such as fishing nets and rugs – that have reached the end of their useful life. Such waste is processed to obtain a raw material – caprolactam – with the same chemical and performance characteristics as those from fossil sources. The polymers produced from ECONYL^® caprolactam are distributed to the Group’s production plants, where they are transformed into yarn for rugs, carpet flooring and for clothing.

Founded in 1965, Aquafil is one of the main producers of nylon in Italy and worldwide. The Group is present on three different continents, employing about 2,300 people at 19 production sites located in Italy, Slovenia, Unites States, China, Croatia, Chile, Thailand and Japan.

Contacts
Giulia Rossi
investor.relations@aquafil.com
mob: +39 327 0820 268

• EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo 
• EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT study
• Publication follows a recent FDA label update to expand EMPAVELI’s indication to include reducing the loss of kidney function in patients 12 years and older, in addition to reducing proteinuria

CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology (CJASN). The dedicated subgroup analysis was first presented at the 2025 Annual Meeting of the European Society of Paediatric Nephrology (ESPN).

“C3G and primary IC-MPGN are often diagnosed early in life, when preventing progressive kidney damage can have a meaningful long-term impact,” said Bradley Dixon, M.D., Section Chief of Pediatric Nephrology and Professor of Pediatrics, University of Colorado School of Medicine and Children’s Hospital Colorado. “The VALIANT results show substantial reductions in proteinuria and stabilization of kidney function in adolescents, consistent with what we observed in the broader population. These findings are especially encouraging for young patients who may otherwise face a lifetime of progressive kidney disease leading to a potential kidney transplant.”

The analysis showed that a cohort of adolescents aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) treated with EMPAVELI achieved clinically meaningful reductions in proteinuria and stabilization of kidney function compared with placebo. The findings were consistent with results from the overall VALIANT population.

Adolescents represented nearly half of the VALIANT study population, providing one of the largest randomized datasets in this age group for C3G and primary IC-MPGN.

Among the adolescent cohort (n= 55) at Week 26, results included:

• EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria versus placebo (95% CI: 59%-84%; nominal p<0.001), with reductions observed as early as Week 4 and continuing through Week 26.
• 71% of adolescents treated with EMPAVELI achieved at least a 50% reduction in proteinuria, compared with 4% receiving placebo (nominal p<0.001).
• 57% of EMPAVELI-treated adolescents achieved both stable kidney function and at least a 50% reduction in proteinuria, compared with 4% receiving placebo (nominal p=0.002).

The publication follows the recent FDA-approved label expansion for EMPAVELI, making it the first and only therapy approved to reduce both proteinuria and the loss of kidney function in adults and adolescents aged 12 years and older. The label update was based on 52-week efficacy and safety data from the VALIANT study demonstrating substantial reductions in proteinuria and sustained preservation of kidney function, as measured by estimated glomerular filtration rate (eGFR).

“The results published in the Clinical Journal of the American Society of Nephrology further strengthen our confidence in the benefits EMPAVELI can provide for adolescents living with C3G and primary IC-MPGN,” said Daniel Jones, Ph.D., Vice President, Head of Global Medical Affairs for EMPAVELI at Biogen. “Together with the recent expansion of the U.S. indication for EMPAVELI, these findings reinforce the potential for EMPAVELI to help protect patients’ kidney health.”

EMPAVELI was well tolerated in adolescents, with a safety profile consistent with the overall VALIANT population.

About the VALIANT Study

VALIANT (NCT05067127) was a randomized, placebo-controlled, double-blind, multicenter Phase 3 study evaluating the efficacy and safety of EMPAVELI in 124 patients aged 12 years and older with C3G or primary IC-MPGN.

The trial included both adolescent and adult patients with native kidney disease or post-transplant disease recurrence. Participants were randomized to receive EMPAVELI or placebo twice weekly for 26 weeks, followed by a 26-week open-label period in which all patients received EMPAVELI. The primary endpoint was the change in urine protein-to-creatinine ratio (UPCR) at Week 26 compared with baseline.

About C3 Glomerulopathy and Primary IC-MPGN

C3G and primary IC-MPGN are rare, chronic, complement-mediated kidney diseases that can lead to progressive kidney damage and kidney failure.

The diseases frequently begin early in life. Approximately half of patients with C3G are diagnosed before age 18, while the median age at diagnosis for primary IC-MPGN is approximately 21 years. Despite standard-of-care treatment, approximately 20% of children with C3G or primary IC-MPGN progress to kidney failure within 10 to 15 years of diagnosis.

About EMPAVELI® (pegcetacoplan)

EMPAVELI® (pegcetacoplan) is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can contribute to the onset and progression of serious diseases.

EMPAVELI is indicated in the United States for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria and the loss of kidney function. EMPAVELI is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).

U.S. Important Safety Information for EMPAVELI

BOXED WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

EMPAVELI, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

• Complete or update vaccination for encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI, unless the risks of delaying therapy with EMPAVELI outweigh the risks of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.
• Patients receiving EMPAVELI are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.

Because of the risk of serious infections caused by encapsulated bacteria, EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the EMPAVELI REMS.

CONTRAINDICATIONS

• Hypersensitivity to pegcetacoplan or to any of the excipients
• For initiation in patients with unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B

WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria

EMPAVELI, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis (caused by any serogroup, including non-groupable strains), and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of EMPAVELI treatment is contraindicated in patients with unresolved serious infection caused by encapsulated bacteria.

Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to administration of the first dose of EMPAVELI, according to the most current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with EMPAVELI. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent EMPAVELI therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. The benefits and risks of treatment with EMPAVELI, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by encapsulated bacteria.

Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of EMPAVELI in patients who are undergoing treatment for serious infections.

EMPAVELI is available only through a restricted program under a REMS.

EMPAVELI REMS

EMPAVELI is available only through a restricted program under a REMS called EMPAVELI REMS, because of the risk of serious infections caused by encapsulated bacteria. Notable requirements of the EMPAVELI REMS include the following:

Under the EMPAVELI REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risks, signs, and symptoms of serious infections caused by encapsulated bacteria, provide patients with the REMS educational materials, ensure patients are vaccinated against encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI, prescribe antibacterial drug prophylaxis if patients’ vaccine status is not up to date and treatment must be started urgently, and provide instructions to always carry the Patient Safety Card both during treatment, as well as for 2 months following last dose of EMPAVELI. Pharmacies that dispense EMPAVELI must be certified in the EMPAVELI REMS and must verify prescribers are certified.

Further information is available at www.empavelirems.com or 1-888-343-7073.

Infusion-Related Reactions

Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria, pyrexia) have occurred in patients treated with EMPAVELI, which may resolve after treatment with antihistamines. Cases of anaphylaxis leading to treatment discontinuation have been reported. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved.

Interference with Laboratory Tests

There may be interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels.

ADVERSE REACTIONS

Most common adverse reactions in adult and pediatric patients 12 years of age and older with C3G or primary IC-MPGN (incidence ≥10%) were infusion-site reactions, pyrexia, nasopharyngitis, influenza, cough, and nausea.

USE IN SPECIFIC POPULATIONS

Females of Reproductive Potential

EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose.

Please see full Prescribing Information, including Boxed WARNING regarding serious infections caused by encapsulated bacteria, and Medication Guide.

About Biogen

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Facebook, Instagram, LinkedIn, X, YouTube.

Biogen Safe Harbor

This news release contains forward-looking statements, relating to, among others, the potential clinical effects of EMPAVELI; the potential benefits, safety and efficacy of EMPAVELI in adolescents with C3G or Primary IC-MPGN; the clinical development program for EMPAVELI; advancing C3G and Primary IC-MPGN research and the treatment of C3G and Primary IC-MPGN; our research and development programs for the treatment of C3G and Primary IC-MPGN; the potential of our commercial business and pipeline programs, including EMPAVELI; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

Biogen Media Contact:
Madeleine Shin
Public.affairs@biogen.com
781-464-3260

Biogen Investor Contact:
Tim Power
IR@biogen.com
781-464-2442

MONTREAL, Sept. 17, 2026 (GLOBE NEWSWIRE) — TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced that Steve Mayer will join its Board of Directors effective October 29, 2026.

Mr. Mayer has more than 30 years of investment banking experience with firms including Goldman Sachs, Morgan Stanley and Greenhill & Co., advising leading Canadian companies on domestic and U.S. cross-border M&A and capital markets transactions. Currently the President of Greenhill Canada and Vice Chairman of Greenhill & Co., Mr. Mayer has had substantial engagement with boards of directors advising on a wide range of complex topics and is known for his entrepreneurial approach and strong leadership skills. Mr. Mayer has also sat on various boards including large not-for-profit organizations in healthcare and other sectors. He received his Bachelor of Commerce and Finance from the University of Toronto and his Master of Business Administration from Columbia Business School.

“Steve’s superb track record in the capital markets and M&A combined with his deep experience in both Canada and the U.S. make him the perfect fit for our Board of Directors and I extend a warm welcome,” stated Alain Bédard, Chairman, President and Chief Executive Officer of TFI International. “Steve is deeply committed to our values around business discipline with a growth mindset, and his Canadian-U.S. knowledge and highly relevant expertise will prove incredibly valuable as TFI International strives to further enhance shareholder value.”

ABOUT TFI INTERNATIONAL
TFI International Inc. is a North American leader in the transportation and logistics industry, operating across the United States, Canada and Mexico through its subsidiaries. TFI International creates value for shareholders by identifying strategic acquisitions and managing a growing network of wholly-owned operating subsidiaries. Under the TFI International umbrella, companies benefit from financial and operational resources to build their businesses and increase their efficiency. TFI International companies service the following segments:

• Less-Than-Truckload;
• Truckload;
• Logistics.

TFI International Inc. is publicly traded on the New York Stock Exchange and the Toronto Stock Exchange under the symbol TFII. For more information, visit www.tfiintl.com.

For further information:
Alain Bédard
Chairman, President and CEO
TFI International Inc.
647-729-4079
abedard@tfiintl.com

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Base Shelf Prospectus Accessible and Prospectus Supplement to be Accessible on SEDAR+

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — First Mining Gold Corp. (“First Mining” or the “Company”) (TSX: FF) (FRANKFURT: FMG) is pleased to announce that it has entered into an agreement with Haywood Securities Inc., ATB Cormark Capital Markets, and National Bank Financial Inc. acting as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters (collectively, the “Underwriters“), pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 59,530,000 common shares of the Company (the “Common Shares”) at a price of $0.84 per Common Share (the “Offering Price”) for aggregate gross proceeds to the Company of $50,005,200 (the “Offering”). The Underwriters have been granted an option (an “Over-Allotment Option“) to purchase up to an additional 15% of the number of Common Shares issuable under the Offering at the Offering Price, exercisable in whole or in part up to 30 days following the closing of the Offering, which may be exercised to cover over-allotments, if any, and for market stabilization purposes.

The net proceeds from the Offering will be used to advance First Mining’s Springpole and Duparquet gold projects, as well as for general working capital and corporate purposes.

The Common Shares will be offered by way of a prospectus supplement (the “Supplement”) to the Company’s base shelf prospectus dated February 23, 2026 (the “Base Shelf Prospectus”) in each of the provinces and territories of Canada (excluding Quebec). The Common Shares may also be offered by way of private placement in the United States and in offshore jurisdictions in accordance with applicable securities laws and where doing so would not require a prospectus, registration statement, offering memorandum or similar document, or create reporting or other obligations for the Company. The Offering is expected to close on or about September 24, 2026, and is subject to customary closing conditions, including but not limited to the Company receiving all necessary regulatory approvals, including the approval of the Toronto Stock Exchange (the “TSX”).

Access to the Base Shelf Prospectus, the Supplement and any amendments to such documents are provided in accordance with securities legislation relating to procedures for providing access to a base shelf prospectus, a shelf prospectus supplement and any amendment to such documents. The Shelf Prospectus is accessible, and the Supplement will be accessible within two business days from the date hereof, under the Company’s profile on SEDAR+ at www.sedarplus.ca. Copies of the Base Shelf Prospectus, the Supplement, and any amendment to such documents may be obtained, without charge, from: (i) Haywood Securities Inc., by phone at (604) 697-7126 or by email at ecm@haywood.com, (ii) ATB Cormark Capital Markets, by phone at (416) 943-6701 or by email at ecm@atb.ca, or (iii) National Bank Financial Inc., by phone at (416) 869-8414 or by email at NBF-Syndication@bnc.ca. Before investing, prospective investors should read the Base Shelf Prospectus, the Supplement, when available, and the documents incorporated by reference therein.

The Common Shares offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Common Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About First Mining Gold Corp.

First Mining is a gold developer advancing two of the largest gold projects in Canada, the Springpole Gold Project in northwestern Ontario, where the federal Environmental Assessment for the Springpole Project was approved in June 2026, and the Duparquet Gold Project in Quebec, a PEA-stage development project located on the Destor-Porcupine Fault Zone in the prolific Abitibi region. First Mining also owns a 20% project interest in the Pickle Crow Gold Project in Ontario and large equity interest in Seva Mining Corp.

First Mining was established in 2015 by Mr. Keith Neumeyer, founder and CEO of First Majestic Silver Corp.

ON BEHALF OF FIRST MINING GOLD CORP.

Daniel W. Wilton
Chief Executive Officer and Director

For further information, please contact:

Toll Free: 1 844 306 8827 | Email: info@firstmininggold.com
Paul Morris | Director, Investor Relations | Email: paul@firstmininggold.com  

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date of this news release. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “plans”, “projects”, “intends”, “estimates”, “envisages”, “potential”, “possible”, “strategy”, “goals”, “opportunities”, “objectives”, or variations thereof or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions.

Forward-looking statements in this news release relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events and include, but are not limited to, statements with respect to the closing of the Offering and the timing of same, the use of the proceeds of the Offering, and the exercise of the Over-Allotment Option. All forward-looking statements are based on First Mining’s or its consultants’ current beliefs as well as various assumptions made by them and information currently available to them. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to: the Company’s ability to obtain all approvals required in connection with the Offering; feasibility and permitting activities related to the Springpole Gold Project; realizing the value of the Company’s gold projects for the Company’s shareholders; Company’s business strategy; future planning processes. Statements concerning proven and probable mineral reserves and mineral resource estimates may also be deemed to constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered as and if the property is developed, and in the case of measured and indicated mineral resources or proven and probable mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.

Forward-looking statements reflect the beliefs, opinions and projections of management on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Such factors include, without limitation the Company’s business, operations and financial condition potentially being materially adversely affected by the outbreak of epidemics, pandemics or other health crises, and by reactions by government and private actors to such outbreaks; risks to employee health and safety as a result of the outbreak of epidemics, including pandemics or other health crises, that may result in a slowdown or temporary suspension of operations at some or all of the Company’s mineral properties as well as its head office; fluctuations in the spot and forward price of gold, silver, base metals or certain other commodities; fluctuations in the currency markets (such as the Canadian dollar versus the U.S. dollar); changes in national and local government, legislation, taxation, controls, regulations and political or economic developments; requirements for additional capital; changes in project parameters as plans continue to be refined; variations in ore reserves, grade or recovery rates; actual performance of plant, equipment or processes relative to specifications and expectations; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins and flooding); effectiveness of environmental mitigations and strategies including production of NAG and PAG tailings and mine rock and water management strategies, the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities, indigenous populations and other stakeholders; availability and increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development; title to properties; and the additional risks described in the Company’s Annual Information Form for the year ended December 31, 2025 filed with the Canadian securities regulatory authorities under the Company’s SEDAR+ profile at www.sedarplus.ca, and in the Company’s Annual Report on Form 40-F filed with the SEC on EDGAR.

First Mining cautions that the foregoing list of factors that may affect future results is not exhaustive. When relying on our forward-looking statements to make decisions with respect to First Mining, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. First Mining does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by the Company or on our behalf, except as required by law. 

GREAT NECK, N.Y., Sept. 17, 2026 (GLOBE NEWSWIRE) — BRT APARTMENTS CORP. (NYSE: BRT) announced today that its Board of Directors declared a quarterly dividend of $0.25 per share. The dividend is payable October 6, 2026, to stockholders of record at the close of business on September 28, 2026. The Board of Directors also announced that it approved, with respect to its share repurchase program that expires on December 31, 2028, a replenishment in the value of the shares to be repurchased pursuant to such program to $10 million.

BRT is a real estate investment trust that owns and operates multifamily properties. These multifamily properties may be wholly owned by BRT or by unconsolidated joint ventures in which BRT contributed a portion of the equity. As of September 17, 2026, BRT owns or has interests in 31 multi-family properties with 8,311 units in 11 states and has preferred equity investments in two multifamily properties. For additional information on BRT’s operations, activities and properties, please visit its website at www.brtapartments.com.

Contact:

BRT APARTMENTS CORP.
60 Cutter Mill Road
Suite 303
Great Neck, New York 11021
Telephone: (516) 466-3100
Email: investors@BRTapartments.com
www.BRTapartments.com

ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) — The attached notification relates to the purchase of ordinary shares by a member of the Company’s Board of Directors.

Attachment

• notification-of-managers-transaction-lionel-carnot-14-september-2026

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) will be presenting at the following conferences in September with webcasts available at Nasdaq’s Investor Relations website: https://ir.nasdaq.com/.

Who:	Tal Cohen, President, Nasdaq
What:	Autonomous 2026 Future of Commerce Symposium
When:	Wednesday, September 23rd, 1:00 PM ET
Who:	Sarah Youngwood, Executive Vice President & Chief Financial Officer, Nasdaq
What:	Bank of America Securities 31st Annual Financials CEO Conference
When:	Thursday, September 24th, 3:00 AM ET / 8:00 AM BST

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the infrastructure of the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying advanced technology, data, and intelligence solutions that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at  www.nasdaq.com.

Media Relations Contact:
David Lurie
+1.914.538.0533
David.Lurie@Nasdaq.com

Investor Relations Contact:
Ato Garrett
+1.212.401.8737
Ato.Garrett@Nasdaq.com

-NDAQF-

SAXONBURG, Pa., Sept. 17, 2026 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: OHR), the global leader in photonics, today announced the expansion of its Pluggable Optical Line System (POLS) portfolio, with the full C-band, high-power variable-gain amplifier optical line system in a compact QSFP form factor. Designed for the latest generation of 800G ZR/ZR+ digital coherent optics, the enhanced POLS supports up to 32 DWDM wavelengths over a single fiber pair, enabling as much as 25.6Tbps of AI datacenter traffic across links from 2km to 200km.

Targeting the high-capacity interconnect requirements of Internet Service and Cloud Hosting Providers, and AI infrastructure operators, the enhanced POLS integrates key optical transport functions into QSFP modules that plug directly into standard transceiver slots. Thanks to Coherent’s high-performance miniature optical components, including dual-chip micropump lasers, POLS provides 21dBm output power, variable gain, low power consumption, and autonomous plug-and-play operation. Auto-provisioning manages link configuration and laser safety, while fixed wavelength and colorless MUX/DMUX options and asymmetric optical connectors simplify deployment and help prevent fiber-connection errors.

“As AI infrastructure scales, customers require optical connectivity that combines greater capacity, operational simplicity, and deployment flexibility,” said Madhu Krishnaswamy, Senior Vice President, Telecom Transport Business Unit at Coherent. “Since we first introduced POLS, Coherent has continued to advance the ultra-compact optical components that enable this platform, including our dual-chip 700mW uncooled 3-pin 980nm pump laser and isolator-tap photodiode technology. By extending plug-and-play operation across the full C-band, we are helping customers reduce the traditional tradeoffs between performance and operational simplicity. This advancement represents another important step toward more automated, open, and high-capacity optical networks for the AI era.”

The enhanced POLS is generally available and shipped in high volume. Coherent offers versions supporting 400G and 800G ZR and ZR+ applications with either SFF-8636 or CMIS 4.0 memory maps, enabling straightforward deployment in existing network environments.

Visitors to ECOC 2026 are invited to experience the latest POLS technology at the Coherent Booth #2100. Additional product information is available at www.coherent.com.

About Coherent 

Coherent is the global photonics leader. We harness photons to drive innovation. Industry leaders in the datacenter, communications, and industrial markets rely on Coherent’s world-leading technology to fuel their own innovation and growth.

Founded in 1971 and operating in more than 20 countries, Coherent brings the industry’s broadest, deepest technology stack; unmatched supply chain resilience; and global scale to help its customers solve their toughest technology challenges. For more information, visit us at coherent.com.

Media Contact:
innovations@coherent.com 

BOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) — Rapid7, Inc. (“Rapid7”) (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, announced that the company granted inducement awards, effective as of September 15, 2026, to employees as a material inducement to commence employment with Rapid7 and its subsidiaries.

We granted inducement awards comprised of 290,626 restricted stock units (“RSUs”) in respect of Rapid7’s common stock, in the aggregate, to 3 employees.

The RSUs vest over a three-year period with one-third (1/3) of the RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining two-thirds (2/3) of the RSUs vesting in equal quarterly installments thereafter through the third anniversary of the vesting commencement date, subject to continued employment through each applicable vesting date.

The RSUs were granted under Rapid7’s 2015 Equity Incentive Plan, as amended (the “Equity Plan”) pursuant to the Equity Plan’s inducement award share pool. The RSUs were unanimously approved by Rapid7’s Compensation Committee, which is independent within the meaning of Nasdaq Listing Rule 5605(a)(2), in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for the employees to commence employment with Rapid7.

About Rapid7

Rapid7, Inc. (NASDAQ: RPD) is a global leader in AI-powered managed cybersecurity operations, trusted to advance organizations’ cyber resilience. Open and extensible, the Rapid7 Command Platform integrates security data, enriching it with AI, threat intelligence, and 25 years of expertise and innovation to reduce risk and disrupt attackers. As a recognized leader in preemptive managed detection and response (MDR), Rapid7 unifies exposure and detection to transform the cybersecurity operations of more than 11,500 customers worldwide. For more information, visit our website, check out our blog, or follow us on LinkedIn or X.

Rapid7 Press Contact
Christine Nurnberger
SVP Global Marketing and Growth 
press@rapid7.com

Rapid7 Investor Contact
Ryan Flanagan and Ryan Gardella
ICR for Rapid7
investors@rapid7.com
(617) 865-4277

Source: Rapid7